目的 评价替吉奥胶囊单药三线治疗老年晚期结直肠癌的有效性与安全性.方法观察32例明确诊断的老年晚期结直肠癌患者,接受三线替吉奥胶囊单药治疗.每治疗2个周期后按RECIST标准评价疗效,同时按CTCAE标准评价安全性,并观察无进展生存期.结果 32例患者中有4例因不良反应仅接受1周期化疗不能评价疗效,28例可评价患者中PR 7.14 %(2/28),SD 46.43%(13/28),PD 46.43%(13/28).严重不良反应包括:1例Ⅳ度骨髓抑制伴全消化道黏膜炎、1例Ⅲ度恶心伴厌食、2例Ⅲ度腹泻.余不良反应主要为皮肤色素沉着、转氨酶升高等,耐受性良好.随访至2011年11月,中位无进展生存期为3.3个月.结论替吉奥胶囊单药三线治疗老年晚期结直肠癌,有一定的疗效,给药方便,价格适中,不良反应可耐受,值得临床进一步探索.%Objective To evaluate the efficacy and safety of tegafur, gimeracil and oteracil potassium capsules as line-3 treatment in elderly patients with advanced colorectal cancer. Methods 32 elderly patients with advanced colorectal cancer received tegafur, gimeracil and oteracil potassium capsules as line-3 treatment. After every two cycles, therapeutic efficacy was evaluated according to RECIST version 1.1. Adverse reactions were assessed during treatment according to CTCAE version 3.0. The progression-free survival was observed. Results 4 patients who only received 1 cycle chemotherapy due to adverse reactions were ruled out of evaluation. In 28 evaluable patients, 2 patients had partial responses (7.14%), 13 patients had stable diseases (46.43%) and 13 patients had progressive diseases (46.43%). The serious adverse reactions were IV degree bone marrow suppression with total tract mucositis (1 patient), M degree nausea with anorexia (1 patient) and M degree diarrhea (2 patients). The other adverse reactions including pigmentation, transaminase increasing, etc. Were well tolerated. All cases were followed up to November 2011, the median progression-free survival was 3.3 months. Conclusion Tegafur, gimeracil and oteracil potassium capsules as line-3 treatment in elderly patients with advanced clorectal cancer have advantages of good efficacy, convenient administration, moderate prices and well tolerance, which deserve further study.
展开▼
